Prediction of outcome of patients with metastatic breast cancer: Evaluation with prognostic factors and Nottingham prognostic index

Supportive Care in Cancer

Volumn 18, Issue 12, 2010, Pages 1553-1564

  Liu, Mu Tai ^a,b,c,d   Huang, Wen Tao ^c   Wang, Ai Yih ^c   Huang, Chia Chun ^a   Huang, Chao Yuan ^b   Chang, Tung Hao ^a   Pi, Chu Pin ^a   Yang, Hao Han ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

HER2 overexpression; Metastatic breast cancer; Prognostic index; Trastuzumab

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; VINCA ALKALOID;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE INTERVAL; DISTANT METASTASIS; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOTTINGHAM PROGNOSTIC INDEX; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TAIWAN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78349310182     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0778-0     Document Type: Article

References (86)

1. DL Ahmann DJ Schaid JN Ingle HF Bisel AJ Schutt JC Buckner HJ Long J Rubin 1991 A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer Am J Clin Oncol 14 179 183 1:STN:280: DyaK3M3jtl2nsw%3D%3D 10.1097/00000421-199106000-00001 2031502
2. S Asaka T Fujimoto J Akaishi K Ogawa M Onda 2006 Genetic prognostic index influences patient outcome for node-positive breast cancer Surg Today 36 793 801 10.1007/s00595-006-3261-2 16937283 (Pubitemid 44306193)
3. J Baselga D Tripathy J Mendelsohn S Baughman CC Benz L Dantis NT Sklarin AD Seidman CA Hudis J Moore PP Rosen T Twaddell IC Henderson L Norton 1996 Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 737 744 1:CAS:528:DyaK28Xit1Gjs7w%3D 8622019
4. JR Benson I Jatoi M Keisch FJ Esteva A Makris VC Jordan 2009 Early breast cancer Lancet 373 1463 1479 10.1016/S0140-6736(09)60316-0 19394537
5. S Beslija J Bonneterre H Burstein V Cocquyt M Gnant P Goodwin V Heinemann J Jassem WJ Köstler M Krainer S Menard T Petit L Petruzelka K Possinger P Schmid E Stadtmauer M Stockler S Van Belle C Vogel N Wilcken C Wiltschke CC Zielinski H Zwierzina 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 215 225 1:STN:280:DC%2BD2s7ptFCkug%3D%3D 10.1093/annonc/mdl155 16831851 (Pubitemid 46323085)
6. I Bièche P Onody S Tozlu K Driouch M Vidaud R Lidereau 2003 Prognostic value of ERBB family mRNA expression in breast carcinomas Int J Cancer 106 758 765 10.1002/ijc.11273 12866037 (Pubitemid 36993401)
7. MC Bissery D Guenard F Gueritte-Voegelein F Lavelle 1991 Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue Cancer Res 51 4845 4852 1:CAS:528:DyaK3MXmt1aqsbg%3D 1680023
8. AU Buzdar 2003 Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer Oncologist 8 335 341 1:CAS:528:DC%2BD3sXmvFSqt78%3D 10.1634/theoncologist.8-4-335 12897330 (Pubitemid 36934482)
9. A Buzdar J Douma N Davidson R Elledge M Morgan R Smith L Porter J Nabholtz X Xiang C Brady 2001 Phase III, multicenter, double blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate J Clin Oncol 19 3357 3366 1:CAS:528:DC%2BD3MXlvVamsro%3D 11454883
10. A Buzdar W Jonat A Howell SE Jones C Blomqvist CL Vogel W Eiermann JM Wolter M Azab A Webster PV Plourde 1996 Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group J Clin Oncol 14 2000 2011 1:CAS:528:DyaK28XksFejtrY%3D 8683230
11. M Campone H Cortes-Funes D Vorobiof M Martin CF Slabber E Ciruelos E Bourbouloux C Mendiola FM Delgado C Colin V Aslanis P Fumoleau 2006 Vinflunine: a new active drug for second-line line treatment of advanced breast cancer. Results of Phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy Br J Cancer 95 1161 1166 1:CAS:528:DC%2BD28XhtFChs7%2FJ 10.1038/sj.bjc.6603347 17031408 (Pubitemid 44658478)
12. SM Campos JP Guastalla M Subar P Abreu EP Winer DA Cameron 2009 A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases Clin Breast Cancer 9 39 44 1:CAS:528:DC%2BD1MXksF2kurw%3D 10.3816/CBC.2009.n.007 19299239
13. CL Carter C Allen DE Henson 1989 Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 181 187 1:STN:280:DyaL1M%2FovFCqug%3D%3D 10.1002/1097-0142(19890101)63:1<181::AID- CNCR2820630129>3.0.CO;2-H 2910416 (Pubitemid 19032001)
14. SH Cheng CF Horng JL Clarke MH Tsou SY Tsai CM Chen JJ Jian MC Liu M West AT Huang LR Prosnitz 2006 Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients Int J Radiat Oncol Biol Phys 64 1401 1409 16472935
15. M Cianfrocca LJ Goldstein 2004 Prognostic and predictive factors in early-stage breast cancer Oncologist 9 606 616 10.1634/theoncologist.9-6-606 15561805 (Pubitemid 39546402)
16. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
17. M Colozza E De Azambuja N Personeni F Lebrun MJ Piccart F Cardoso 2007 Achievements in systemic therapies in the pregenomic era in metastatic breast cancer Oncologist 12 253 270 1:CAS:528:DC%2BD2sXlsVSqtbw%3D 10.1634/ theoncologist.12-3-253 17405890 (Pubitemid 46556792)
18. G D'Eredita' C Giardina M Martellotta T Natale F Ferrarese 2001 Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution Eur J Cancer 37 591 596 10.1016/S0959-8049(00)00435-4 11290434 (Pubitemid 32261016)
19. A Di Leo HL Gomez Z Aziz Z Zvirbule J Bines MC Arbushites SF Guerrera M Koehler C Oliva SH Stein LS Williams J Dering RS Finn MF Press 2008 Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 5544 5552 10.1200/JCO.2008.16.2578 18955454
20. E Dobbe K Gurney S Kiekow JS Lafferty JM Kolesar 2008 Gene-expression assays: new tools to individualize treatment of early-stage breast cancer Am J Health Syst Pharm 65 23 28 1:CAS:528:DC%2BD1cXhtlSjsbY%3D 10.2146/ajhp060352 18159035
21. P Dombernowsky I Smith G Falkson R Leonard L Panasci J Bellmunt W Bezwoda G Gardin A Gudgeon M Morgan A Fornasiero W Hoffmann J Michel T Hatschek T Tjabbes HA Chaudri U Hornberger PF Trunet 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 453 461 1:CAS:528:DyaK1cXhtFSht7c%3D 9469328
22. M Dowsett AK Dunbier 2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer Clin Cancer Res 14 8019 8026 1:CAS:528:DC%2BD1cXhsV2it7rM 10.1158/1078-0432.CCR-08-0974 19088018
23. G Gasparini F Pozza AL Harris 1993 Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients J Natl Cancer Inst 85 1206 1219 1:STN:280:DyaK3szitlWnsA%3D%3D 10.1093/jnci/85.15.1206 8331681
24. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
25. PA Greenberg GN Hortobagyi TL Smith LD Ziegler DK Frye AU Buzdar 1996 Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 2197 2205 1:CAS:528:DyaK28XltFSqsLk%3D 8708708
26. BA Gusterson A Gelber A Goldhirsch KN Price J Save-Soderborgh R Anbazhagan J Styles CM Rudenstam R Golouh R Reed 1992 Prognostic importance of c-erb-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049 1056 1:STN:280:DyaK38zgtVCjtA%3D%3D 1351538
27. L Harris H Fritsche R Mennel L Norton P Ravdin S Taube MR Somerfield DF Hayes RC Bast Jr 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 1:CAS:528:DC%2BD2sXhsVKnsbzK 10.1200/JCO.2007.14.2364 17954709 (Pubitemid 350232263)
28. MJ Hayat N Howlader ME Reichman BK Edwards 2007 Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program Oncologist 12 20 37 10.1634/theoncologist.12-1-20 17227898 (Pubitemid 46143500)
29. DF Hayes B Trock AL Harris 1998 Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 52 305 319 1:STN:280:DyaK1M7mtl2ksA%3D%3D 10.1023/A:1006197805041 10066089 (Pubitemid 29056102)
30. GN Hortobagyi TL Smith SS Legha KD Swenerton EA Gehan HY Yap AU Buzdar GR Blumenschein 1983 Multivariate analysis of prognostic factors in metastatic breast cancer J Clin Oncol 1 776 786 1:STN:280:DyaL2c7jslOksA%3D%3D 6668494
31. HC Hsu HK Chang YC Lin S Hseu JS Chen TS Yang HM Wang WC Shen 2009 The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin Chang Gung Med J 32 33 41 19292937
32. CS Huang SH Kuo HC Lien SY Yang SL You CY Shen CH Lin YS Lu KJ Chang 2008 The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers Oncologist 13 751 760 1:CAS:528:DC%2BD1cXhtVCqtbvI 10.1634/theoncologist.2007-0246 18614591
33. W Jonat A Howell C Blomqvist W Eiermann G Winblad C Tyrrell L Mauriac H Roche S Lundgren R Hellmund M Azab 1996 A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer Eur J Cancer 32A 404 412 1:CAS:528:DyaK28XisFyitLs%3D 10.1016/0959-8049(95)00014-3 8814682
34. SE Jones 2008 Metastastic breast cancer: the treatment challenge Clin Breast Cancer 8 224 233 1:CAS:528:DC%2BD1cXovFCiu7s%3D 10.3816/CBC.2008.n.025 18650152 (Pubitemid 351962143)
35. RL Jones J Salter R A'Hern A Nerurkar M Parton JS Reis-Filho IE Smith M Dowsett 2009 The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 53 68 1:CAS:528:DC%2BD1MXntFaktbY%3D 10.1007/s10549-008-0081-7 18592370
36. F Kassam K Enright R Dent G Dranitsaris J Myers C Flynn M Fralick R Kumar M Clemons 2009 Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 9 29 33 10.3816/CBC.2009.n.005 19299237
37. M Kaufmann E Bajetta LY Dirix LE Fein SE Jones N Zilembo JL Dugardyn C Nasurdi RG Mennel J Cervek C Fowst A Polli E di Salle A Arkhipov G Piscitelli LL Miller G Massimini 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. The Exemestane Study Group J Clin Oncol 18 1399 1411 1:CAS:528:DC%2BD3cXivVeisrw%3D 10735887
38. JG Klijn RW Blamey F Boccardo T Tominaga L Duchateau R Sylvester Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer 2001 Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 343 353 1:CAS:528:DC%2BD3MXhtVekt74%3D 11208825
39. Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP (2009) The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol (in press)
40. AK Koutras KT Kalogeras MA Dimopoulos RM Wirtz U Dafni E Briasoulis D Pectasides H Gogas C Christodoulou G Aravantinos G Zografos E Timotheadou P Papakostas H Linardou E Razis T Economopoulos HP Kalofonos G Fountzilas Hellenic Cooperative Oncology Group (HeCOG) 2008 Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study Br J Cancer 99 1775 1785 1:CAS:528:DC%2BD1cXhsVajtbrI 10.1038/sj.bjc.6604769 18985033
41. WH Kuo AM Yen PH Lee KM Chen J Wang KJ Chang TH Chen HS Tsau 2009 Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women Br J Cancer 100 563 570 10.1038/sj.bjc.6604898 19190627
42. NL Liberato M Marchetti G Barosi 2007 Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 25 625 633 10.1200/JCO.2006.06.4220 17308267 (Pubitemid 350002916)
43. PP Lin DC Allison J Wainstock, et al. 1993 Impact of axillary lymph node dissection on the therapy of breast cancer patients J Clin Oncol 11 1536 1544 1:STN:280:DyaK3szivFCqug%3D%3D 8336192
44. YC Lin HK Chang JS Chen HM Wang TS Yang CC Liaw 2007 A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis Jpn J Clin Oncol 37 23 29 10.1093/jjco/hyl124 17172351 (Pubitemid 47090720)
45. CH Lin JY Liau YS Lu CS Huang WC Lee KT Kuo YC Shen SH Kuo C Lan JM Liu WH Kuo KJ Chang AL Cheng 2009 Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia Cancer Epidemiol Biomarkers Prev 18 1807 1814 1:CAS:528:DC%2BD1MXmvF2jsrY%3D 10.1158/1055-9965.EPI-09-0096 19505913
46. H Lueck GV Minckwitz A Du Bois I Schrader J Huober V Heilmann M Beckmann A Stähle C Jackisch C Marth B Richter 2006 Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group J Clin Oncol 24 suppl 18 517
47. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Antón A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group J Clin Oncol 23 4265 4274 1:CAS:528: DC%2BD2MXms12gs70%3D 10.1200/JCO.2005.04.173 15911866 (Pubitemid 46207001)
48. DR McCready JA Chapman WM Hanna HJ Kahn D Murray EB Fish ME Trudeau IL Andrulis HL Lickley 2000 Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model Ann Surg Oncol 7 416 426 1:STN:280:DC%2BD3M%2FlsFCmtg%3D%3D 10.1007/s10434-000-0416-z 10894137
49. DV Miller AA Leontovich WL Lingle VJ Suman ML Mertens J Lillie KA Ingalls EA Perez JN Ingle FJ Couch DW Visscher 2004 Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas Mod Pathol 17 756 764 1:CAS:528:DC%2BD2cXmsVOis78%3D 10.1038/modpathol.3800114 15073601 (Pubitemid 38843357)
50. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D 10.1056/NEJMoa072113 18160686
51. HT Mouridsen C Rose AH Brodie IE Smith 2003 Challenges in the endocrine management of breast cancer Breast 12 Suppl 2 S2 S19 10.1016/S0960-9776(03) 80158-3 14659138 (Pubitemid 40023558)
52. A Naresh AD Thor SM Edgerton KC Torkko R Kumar FE Jones 2008 The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis Cancer Res 68 6387 6395 1:CAS:528: DC%2BD1cXpt1Wjt74%3D 10.1158/0008-5472.CAN-08-0538 18676864
53. AM Neville R Bettelheim RD Gelber RD Gelber J Säve-Söderbergh BW Davis R Reed J Torhorst R Golouh HF Peterson KN Price 1992 Factors predicting treatment responsiveness and prognosis in node-negative breast cancer J Clin Oncol 10 696 705 1:STN:280:DyaK383jsFKlsA%3D%3D 1569442
54. H Okugawa D Yamamoto Y Uemura N Sakaida M Yamada K Tanaka Y Kamiyama 2005 Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution Surg Today 35 907 911 10.1007/s00595-005-3056-x 16249842 (Pubitemid 41540057)
55. CK Osborne 1992 Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10 679 682 1:STN:280:DyaK383jsFKmuw%3D%3D 1569440
56. V Pawlowski F Révillion M Hebbar L Hornez JP Peyrat 2000 Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay Clin Cancer Res 6 4217 4225 1:CAS:528:DC%2BD3cXovVSgtbo%3D 11106235
57. RJ Pietras J Arboleda DM Reese N Wongvipat MD Pegram L Ramos CM Gorman MG Parker MX Sliwkowski DJ Slamon 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 2435 2446 1:CAS:528:DyaK2MXmsFCgtr4%3D 7784095
58. RJ Pietras BM Fendly VR Chazin MD Pegram SB Howell DJ Slamon 1994 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1829 1838 1:CAS:528:DyaK2cXltVKhs78%3D 7911565
59. K Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell MN Levine National Cancer Institute of Canada Clinical Trials Group 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 1:CAS:528:DC%2BD28XkslCku7s%3D 10.1056/NEJMoa054504 16707747 (Pubitemid 43736610)
60. PM Ravdin LA Siminoff GJ Davis MB Mercer J Hewlett N Gerson HL Parker 2001 Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 980 991 1:STN:280: DC%2BD3M3gsFalsg%3D%3D 11181660
61. JF Robertson AR Dixon RI Nicholson IO Ellis CW Elston RW Blamey 1992 Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy Breast Cancer Res Treat 22 221 227 1:STN:280:DyaK3s%2FgsVyisQ%3D%3D 10.1007/BF01840835 1391988
62. M Robinovich C Vallejo A Bianco J Perez M Machiavelli B Leone A Romero R Rodriguez M Cuevas C Dansky F Xynos L Alvarez 1992 Development and validation of prognostic models in metastatic breast cancer: a GOCS Study Oncology 49 188 195 10.1159/000227037
63. PP Rosen S Groshen DW Kinne L Norton 1993 Factors influencing prognosis in node negative breast carcinoma: analysis of 767 TINOMO/T2NOMO patients with long term follow-up J Clin Oncol 11 2090 2100 1:STN:280:DyaK2c%2FksFyisA%3D%3D 8229123
64. LB Saltz S Clarke E Díaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzén J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 10.1200/JCO.2007.14.9930 18421054
65. BP Schneider M Wang M Radovich GW Sledge S Badve A Thor DA Flockhart B Hancock N Davidson J Gralow M Dickler EA Perez M Cobleigh T Shenkier S Edgerton KD Miller 2008 Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 4672 4678 1:CAS:528:DC%2BD1cXht1KqtLfE 10.1200/JCO.2008.16.1612 18824714
66. FA Shepherd MS Tsao 2006 Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy J Clin Oncol 24 1219 1220 10.1200/JCO.2005.04.4420 16505443 (Pubitemid 46638822)
67. A Sidoni G Bellezza A Cavaliere R Del Sordo M Scheibel E Bucciarelli 2004 Prognostic indexes in breast cancer: comparison of the Nottingham and Adelaide indexes Breast 13 23 27 1:STN:280:DC%2BD2c%2FlvVGjtg%3D%3D 10.1016/j.breast. 2003.08.007 14759712 (Pubitemid 38228584)
68. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
69. GW Sledge Jr 1996 Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer J Clin Oncol 14 2191 2193 8708706
70. I Soerjomataram MWJ Louwman JG Ribot JA Roukema JWW Coebergh 2008 An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Res Treat 107 309 330 1:CAS:528:DC%2BD1cXht1Sgtrw%3D 10.1007/s10549-007- 9556-1 17377838 (Pubitemid 351172108)
71. YF Sun JD Leu SM Chen IF Lin YJ Lee 2009 Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer BMC Cancer 9 13 10.1186/1471-2407-9-13 19144119
72. Z Suo B Risberg MG Kalsson K Willman A Tierens E Skovlund JM Nesland 2002 EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival J Pathol 196 17 25 1:CAS:528: DC%2BD38XhtFOhs7k%3D 10.1002/path.1003 11748637 (Pubitemid 34071574)
73. KD Swenerton SS Legha T Smith GN Hortobagyi EA Gehan HY Yap JU Gutterman GR Blumenschein 1979 Prognostic factors in metastatic breast cancer treated with combination chemotherapy Cancer Res 39 1552 1562 1:STN:280:DyaE1M7ks1ynuw%3D%3D 427797 (Pubitemid 9172673)
74. ML Telli RW Carlson 2009 First-line chemotherapy for metastatic breast cancer Clin Breast Cancer 9 S66 S72 1:CAS:528:DC%2BD1MXptlWgt74%3D 10.3816/CBC.2009.s.007 19596645
75. D Vallböhmer HJ Lenz 2006 Predictive and prognostic molecular markers in outcome of esophageal cancer Dis Esophagus 19 425 432 10.1111/j.1442-2050.2006.00622.x 17069584 (Pubitemid 44644677)
76. S Verma M Clemons 2007 First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy Oncologist 12 785 797 1:CAS:528:DC%2BD2sXpslertbk%3D 10.1634/theoncologist.12-7-785 17673610 (Pubitemid 47328222)
77. J Verweij M Clavel B Chevalier 1994 Paclitaxel (Taxol™) and docetaxel (Taxotere™): not simply two of a kind Ann Oncol 5 495 505 1:STN:280:DyaK2M%2FgtFGrsw%3D%3D 7918121
78. GA Viani SL Afonso EJ Stefano LI De Fendi FV Soares 2007 Adjuvant trastuzumab in the treatment f HER-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 153 163 10.1186/1471-2407-7-153 17686164 (Pubitemid 47354734)
79. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 1:CAS:528:DC%2BD38XhsVGmt7o%3D 10.1200/JCO.20.3.719 11821453 (Pubitemid 34111379)
80. Y Wang JG Klijn Y Zhang AM Sieuwerts MP Look F Yang D Talantov M Timmermans ME Meijer-van Gelder J Yu T Jatkoe EM Berns D Atkins JA Foekens 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 671 679 1:CAS:528:DC%2BD2MXhsVOitLk%3D 15721472
81. MR Williams JH Todd RI Nicholson CW Elston RW Blamey K Griffiths 1986 Survival patterns in hormone treated advanced breast cancer Br J Surg 73 752 755 1:STN:280:DyaL2s%2FgtFWguw%3D%3D 10.1002/bjs.1800730925 3756443
82. J Winstanley T Cooke GD Murray A Platt-Higgins WD George S Holt M Myskov A Spedding BR Barraclough PS Rudland 1991 The long term prognostic significance of c-erbB-2 in primary breast cancer Br J Cancer 63 447 450 1:STN:280: DyaK3M7mslWrtg%3D%3D 1672256
83. CJ Witton JR Reeves JJ Going TG Cooke JM Bartlett 2003 Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J Pathol 200 290 297 1:CAS:528:DC%2BD3sXnvF2gu7c%3D 10.1002/path.1370 12845624 (Pubitemid 36827302)
84. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189 (Pubitemid 350003059)
85. N Yamamoto T Watanabe N Katsumata Y Omuro M Ando H Fukuda Y Takue M Narabayashi I Adachi S Takashima 1998 Construction and validation of a practical prognostic index for patients with metastatic breast cancer J Clin Oncol 16 2401 2408 1:STN:280:DyaK1czivFygsw%3D%3D 9667257
86. KH Yeh YS Lu CH Hsu JF Lin HJ Chao TC Huang CY Chung CS Chang CH Yang AL Cheng 2005 Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer Br J Cancer 92 1013 1018 1:CAS:528:DC%2BD2MXisVyit70%3D 10.1038/sj.bjc.6602469 15770209 (Pubitemid 40546662)